Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAS prevention of ankylosing spondylitis
NL-OMON29047Not yet recruiting
- Sponsor
- Wyeth
- Start
- Aug 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Etanercept with Placebo (2 arms). Primary endpoints: MRI inflammation of sacroiliac joints and/or spine at 16 weeks and MRI inflammation of sacroiliac joints and/or spine at 6 months. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON29047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29047.